These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36352305)

  • 1. Prevalence of Drugs and Drug Combinations that Increase Risk of Prolonged QT Time Among People with Major Neurocognitive Disorder Living in Sweden: A Cross-Sectional Registry Study.
    Gustafsson M; Altufaili M; Sjölander M
    Drugs Real World Outcomes; 2023 Mar; 10(1):61-68. PubMed ID: 36352305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
    Vandael E; De WuLf I; Foulon V
    J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
    Then MI; Tümena T; Sledziewska A; Gaßmann KG; Maas R; Fromm MF
    Clin Pharmacol Ther; 2023 Feb; 113(2):435-445. PubMed ID: 36471654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
    Franchi C; Ardoino I; Rossio R; Nobili A; Biganzoli EM; Marengoni A; Marcucci M; Pasina L; Tettamanti M; Corrao S; Mannucci PM;
    Drugs Aging; 2016 Jan; 33(1):53-61. PubMed ID: 26693921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.
    Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
    PLoS One; 2016; 11(5):e0155649. PubMed ID: 27192430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
    Khan Q; Ismail M; Haider I
    Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CredibleMeds
    Then MI; Andrikyan W; Maas R; Fromm MF
    Br J Clin Pharmacol; 2022 Jan; 88(1):226-236. PubMed ID: 34156728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
    Chastang A; Renet S; Corny J; Beaussier H; Petre A; Lillo-Lelouet A; Phan Thi TT; Bézie Y
    Int J Clin Pharm; 2019 Feb; 41(1):42-48. PubMed ID: 30610545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Risk Assessment Among Older Patients with Polypharmacy Using the Clinical Decision Support System Janusmed Risk Profile: A Cross-Sectional Register Study.
    Petersson L; Schörgenhofer C; Askfors Y; Justad H; Dahl ML; Andersson ML
    Drugs Aging; 2023 Apr; 40(4):369-376. PubMed ID: 37039960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
    Khan Q; Ismail M; Haider I; Ali Z
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychotropic drug use among older people with major neurocognitive disorder: a cross-sectional study based on Swedish national registries.
    Kindstedt J; Sjölander M; Lövheim H; Gustafsson M
    Eur J Clin Pharmacol; 2022 Mar; 78(3):477-487. PubMed ID: 34738182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
    Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
    J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
    Khan Q; Ismail M; Haider I; Khan F
    Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.
    Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V
    Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of QT-prolonging medications in US emergency departments, 1995-2009.
    Tay KY; Ewald MB; Bourgeois FT
    Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):9-17. PubMed ID: 23696066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Kumar B; Rawat VS
    J Family Med Prim Care; 2020 Dec; 9(12):6023-6040. PubMed ID: 33681037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.